At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 391–400 of 563 results.
-
Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.
-
Researchers want to find the best dose of JNJ-79635322 to use in people with multiple myeloma or AL amyloidosis. The people in this study have multiple myeloma or AL amyloidosis that keeps growing even after treatment. Multiple myeloma is a cancer of the bone marrow. AL amyloidosis happens when a protein called amyloid builds up in organs and prevents them from working properly.
-
Researchers want to find the best dose of TTI-101 that can be used safely alone and with other drugs for cancer. The people in this study have hepatocellular carcinoma (liver cancer) that has metastasized (spread) or is inoperable (surgically unremovable).
-
Imatinib is a standard long-term therapy for chronic myeloid leukemia (CML). Some people are able to stop taking imatinib after their CML is in remission, but sometimes it comes back and retreatment is needed. In this study, researchers want to see if adding the drug asciminib to imatinib therapy prior to a second attempt at stopping treatment will lead to prolonged treatment-free remission (no evidence of cancer after stopping therapy).
-
Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see how much the drug trastuzumab deruxtecan (T-DXd) can get into brain tumors. The people in this study have glioblastoma or cancer that spread to the brain from other parts of the body. They are scheduled to have brain tumor surgery. In addition, their tumors express (make) a protein called HER2, which boosts cancer cell growth. Researchers want to know if T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
-
Researchers want to see how well epcoritamab with tafasitamab and lenalidomide works in people with lymphoma. The people in this study have diffuse large B cell lymphoma (DLBCL) that came back or keeps growing after treatment.
-
Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.
-
The purpose of this study is to find the highest dose of the investigational drug glofitamab that can be given safely alone or with obinutuzumab in patients with non-Hodgkin lymphoma that came back or continued to grow despite treatment. Glofitamab is a "bispecific antibody" that binds to two different proteins: one found on the surface of cancer cells and one found on the surface of immune cells. Researchers think that glofitamab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Both drugs are given intravenously (by vein).